Ellipses Pharma shared a post on LinkedIn:
“We’re proud to announce that we have entered into an exclusive licence agreement with Innolake Biopharm ( Hangzhou) Co Ltd., to develop ILB-3101, a first-in-class B7H3 targeted ADC with an eribulin payload.
ILB-3101 is designated EP0028 by Ellipses and is the 2nd programme we have in-licensed from an innovative Chinese biotech.
EP0028 is currently in Phase 1 in China and has the potential to treat multiple tumour types and overcome resistance to topoisomerase I-based ADCs.
This is an important addition to our clinical-stage portfolio of differentiated assets and continues our mission to develop cancer drugs for patients with high unmet need globally.
Explore the full press release for more information.”
Tobias Arkenau, CMO and Global Head of Drug Development at Ellipses Pharma, shared this post, adding:
“Another great opportunity for Ellipses.
This B7H3 directed ADC with eribulin payload is the first of its kind entering the clinic. Looking very much forward to develop this molecule with our global network of leading oncology experts!”
More posts featuring Tobias Arkenau.